logo.jpg
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
May 13, 2024 06:05 ET | AC Immune SA
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update Landmark deal announced with Takeda for ACI-24.060 with $100 million upfront and total potential payments for...
Hummingbird.Primary.ColorRGB.png
Hummingbird Bioscience Presents New Preclinical Data Highlighting Next-Generation Antibody-Drug Conjugate Capabilities at PEGS Boston 2024
May 13, 2024 05:30 ET | Hummingbird Bioscience
Hummingbird Bioscience will present next-generation antibody-drug conjugate capabilities at PEGS Boston 2024 for the first time.
Tevogen Logo Notified.png
Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives
May 10, 2024 17:40 ET | Tevogen Bio Inc
$50 million in financing advances operational objectives and bolsters a financial path to positive cashflow with minimal dilution.
OptimiTM-03.jpg
Optimi Health Provides Corporate Update
May 10, 2024 08:50 ET | Optimi Health Corp.
Optimi Health provides corporate update.
GENELUX-Final-Logo-Notagline.png
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
May 09, 2024 16:25 ET | Genelux Corporation
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
Logo.PNG
HilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
May 09, 2024 16:05 ET | HilleVax, Inc.
Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 $272.7 million of cash, cash equivalents and marketable securities as of March 31, 2024 BOSTON, May ...
NeuroSigma.png
NeuroSigma Announces Acceptance into 2024 Cohort of the KidsX Accelerator Program
May 09, 2024 09:00 ET | NeuroSigma, Inc.
LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. today announced its acceptance into the 2024 cohort of the KidsX Accelerator Program. KidsX is a global leader in pediatric digital...
QUOIN-COLORED-LOGO (1).png
Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results
May 09, 2024 08:30 ET | Quoin Pharmaceuticals, Inc.
FDA clearance to recruit teens in both on-going Netherton Syndrome clinical studies U.S. and International patent filed for novel Netherton Syndrome combination product Cash runway extended into...
KBLB logo.jpg
Kraig Biocraft Laboratories Spring Spider Silk Production Trials Exceed Expectations
May 09, 2024 08:05 ET | Kraig Biocraft Laboratories
Kraig Labs (OTCQB:KBLB) BAM-1 spider silk spring production trials exceed expectations and Implementing Next Phase of Its Recombinant Spider Silk Plan
Phathom_Pharm_Logo_RGB.jpg
Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024 08:00 ET | Phathom Pharmaceuticals
Over 17,500 total prescriptions for VOQUEZNA® products have been dispensed, launch-to-date, a 361% increase since last quarterly report Net revenues of $1.9 million reported for the first full...